Fidia Announces Presentation of New Data on a Cartilage Explant Model at Orthopaedic Research Society (ORS) Annual Meeting
Poster Title: Articular Cartilage Lubrication by HYADD®4 Reduces Tissue Strains, Chondrocyte Death, and Apoptosis
Florham Park, NJ, March 9, 2018 – Fidia Farmaceutici, a world leader in the research, development and manufacturing of hyaluronic acid (HA) based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announces new data will be presented at the Annual
Fidia Presents New Data on HYMOVIS® , a Breakthrough in Viscoelastic Technology, at the American Orthopaedic Society for Sports Medicine 2016 Annual Meeting
HYMOVIS® is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties; new data demonstrating long-term benefits of Hymovis® in alleviating osteoarthritis knee pain and stiffness and improving physical function and quality of life will be presented.
PARSIPPANY, N.J., July 5, 2016 – Fidia Farmaceutici S.p.A., a world leader